Benefits
Sustained 5-hour alertness
A single 300 mg dose significantly increases alertness scores vs placebo at 1, 3, and 5 hours post-dose — unusual 5-hour sustained effect for a non-caffeine nootropic. Most caffeine-free alertness ingredients fade within 1-2 hours; enXtra maintains effect over a full work session.
Acute attention and reaction time
A single 300 mg dose improves alertness, simple reaction time, and correct responses while reducing errors. Symbol Digit Coding correct responses are roughly 3x greater than placebo at 30 minutes; Alertness Rating Scale shows ~4x greater change at 2 hours. Simple reaction time improvement sustains over 5 hours.
Caffeine-free profile
Produces no jitters, anxiety, or sleep disruption — unlike caffeine-based energy supplements. Suitable for evening use, caffeine-sensitive individuals, and populations with caffeine restrictions (children, pregnancy, anxiety disorders, heart conditions). Useful for consumers moving away from caffeine.
Reduced fatigue and daytime sleepiness
Reduces fatigue scores 5-6 hours post-supplement vs baseline and placebo. Daytime sleepiness scores (Epworth Sleepiness Scale) also improve. Combined with the alertness data, this supports use for shift workers, students, and others needing sustained cognitive energy through long sessions.
DNA-authenticated species identity
Alpinia galanga is frequently adulterated with closely related species (A. officinarum, A. zerumbet, A. calcarata) in the botanical supply chain. OmniActive's DNA authentication confirms species identity — a real quality advantage given the documented adulteration problem in galangal products.
Synergy with caffeine
Combination with caffeine produces a greater alertness peak and longer duration than either alone, with reduced caffeine decline at the 2-3 hour mark. Useful in pre-workout, energy beverage, and nootropic formulations seeking to extend caffeine's effective window without increasing the caffeine dose itself.
Mechanism of action
Dopamine modulation
Preclinical molecular studies indicate Alpinia galanga's diarylheptanoids modulate dopamine concentrations and dopamine receptor activity — the neurotransmitter system most directly linked to alertness, focus, and motivation. Mechanism distinct from caffeine's adenosine antagonism.
Acetylcholinesterase (AchE) inhibition
A. galanga components inhibit AchE, the enzyme that breaks down acetylcholine. Increased synaptic acetylcholine supports attention, learning, and memory. Same enzyme class targeted by Alzheimer's medications (donepezil, galantamine, rivastigmine) — though enXtra's effect is milder and not clinically positioned for cognitive decline.
No adenosine receptor activity
Unlike caffeine (which blocks adenosine receptors causing alertness plus vasoconstriction and habituation), enXtra works through different pathways. This is why enXtra produces alertness without the typical caffeine side effects — no rebound fatigue, no tolerance development, no sleep disruption when taken late in the day.
No habit-forming tendency
Multi-week supplementation trials document that enXtra's effects remain consistent over time rather than declining with tolerance development. No withdrawal symptoms or dependence observed. Distinguishes enXtra from caffeine, which develops tolerance within weeks and requires escalating doses for equivalent effect.
Clinical trials
Randomized, placebo-controlled trial evaluating 300 mg enXtra alone, 300 mg enXtra + caffeine, and caffeine alone vs placebo for acute alertness effects. Alertness scores measured at 1, 3, and 5 hours post-dose. Published in the Journal of the American College of Nutrition by Srivastava et al. 2017.
Healthy adults. Acute single-dose trial.
300 mg enXtra significantly increased alertness scores vs placebo at 1, 3, and 5 hours post-dose — unusual sustained effect for a non-caffeine nootropic. Combination groups (enXtra + caffeine) showed enhanced and extended alertness vs caffeine alone, with reduced caffeine-related decline at the 2-3 hour mark. No adverse events.
Randomized, double-blind, placebo-controlled crossover study of a single 300 mg enXtra dose. CNS Vital Signs computerized cognitive battery, Visual Analogue Scale, and Epworth Sleepiness Scale measured at baseline, 0.5, 1, 2, and 5 hours post-dose. Published in Advances in Complementary & Alternative Medicine by Eraiah et al. 2023.
62 healthy adults. Single-dose crossover trial with washout.
300 mg enXtra improved alertness, simple reaction time, and correct responses while reducing errors. Symbol Digit Coding test correct responses approximately 3× greater than placebo at 30 minutes. Alertness Rating Scale showed approximately 4× greater change at 2 hours vs placebo. Simple reaction time improvement sustained over 5 hours. Reduced fatigue and daytime sleepiness at 5-6 hours post-dose.